Castle Biosciences Inc. (CSTL) Misses Q1 EPS by 26c

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q1 EPS of ($1.10), $0.26 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $42.04 million versus the consensus estimate of $37.45 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Mannatech (MTEX) Tops Q2 EPS by 53c
• Marchex (MCHX) Reports In-Line Q2 EPS